The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline
Open accessAbstract
BACKGROUND: Abnormal homeostasis of the volume of airway surface liquid in patients with cystic fibrosis is thought to produce defects in mucus clearance and airway defense. Through osmotic forces, hypertonic saline may increase the volume of airway surface liquid, restore mucus clearance, and improve lung function. METHODS: A total of 24 patients with cystic fibrosis were randomly assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) four times daily with or without pretreatment with amiloride. Mucus clearance and lung function were measured during 14-day baseline and treatment periods. RESULTS: Long-term inhalation of hypertonic saline without pretreatment with amiloride (i.e., with placebo pretreatment) resulted in a sustained (> or =8 hours) increase in 1-hour rates of mucus clearance, as compared with those with amiloride pretreatment (14.0+/-2.0 vs. 7.0+/-1.5 percent, respectively; P=0.02) and increased 24-hour rates of mucus clearance over baseline. Furthermore, inhalation of hypertonic saline with placebo improved the forced expiratory volume in one second (FEV1) between the baseline period and the treatment period (mean difference, 6.62 percent; 95 percent confidence interval, 1.6 to 11.7; P=0.02), whereas hypertonic saline with amiloride did not improve FEV1 (mean difference, 2.9 percent; 95 percent confidence interval, -2.2 to 8.0; P=0.23). Forced vital capacity (FVC), the forced expiratory flow between 25 and 75 percent of FVC (FEF25-75), and respiratory symptoms also significantly improved in patients treated with hypertonic saline and placebo, whereas the residual volume as a proportion of total lung capacity (RV:TLC) did not change in either group. A comparison of the changes in lung function in the two groups showed no significant difference. In vitro data suggested that sustained hydration of airway surfaces was responsible for the sustained improvement in mucus clearance, whereas inhibition of osmotically driven water transport by amiloride accounted for the observed loss of clinical benefit. CONCLUSIONS: In patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained acceleration of mucus clearance and improved lung function. This treatment may protect the lung from insults that reduce mucus clearance and produce lung disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81724-9 · Cited by 1,169
Self-citationIncreased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice
Mall, M., Grubb, B. R., Harkema, J. R., O'Neal, W. K., & Boucher, R. C. (2004) · Nature Medicine · doi:10.1038/nm1028 · Cited by 911
Self-citationA Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., & Bye, P. T. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043900 · Cited by 862
Ma, T., Thiagarajah, J. R., Yang, H., Sonawane, N. D., Folli, C., Galietta, L. J. V., & Verkman, A. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216112 · Cited by 536
Normal and Cystic Fibrosis Airway Surface Liquid Homeostasis
Tarran, R., Button, B., Picher, M., Paradiso, A. M., Ribeiro, C. M., Lazarowski, E. R., Zhang, L., Collins, P. L., Pickles, R. J., Fredberg, J. J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505832200 · Cited by 345
Self-citationRobinson, M., Hemming, A. L., Regnis, J. A., Wong, A. G., Bailey, D. L., Bautovich, G. J., King, M., & Bye, P. T. (1997) · Thorax · doi:10.1136/thx.52.10.900 · Cited by 265
Tarran, R., Grubb, B. R., Parsons, D., Picher, M., Hirsh, A. J., Davis, C. W., & Boucher, R. C. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00286-6 · Cited by 259
Self-citationTarran, R., Grubb, B. R., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (2001) · The Journal of General Physiology · doi:10.1085/jgp.118.2.223 · Cited by 249
Self-citationRobinson, M., Regnis, J. A., Bailey, D. L., King, M., Bautovich, G. J., & Bye, P. T. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.5.8630593 · Cited by 232
Cited by
Airway Mucus Function and Dysfunction
Fahy, J. V., & Dickey, B. F. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0910061 · Cited by 1,722
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., & Bye, P. T. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043900 · Cited by 862
What the pulmonary specialist should know about the new inhalation therapies
Laube, B. L., Janssens, H. M., de Jongh, F. H. C., Devadason, S. G., Dhand, R., Diot, P., Everard, M. L., Horvath, I., Navalesi, P., Voshaar, T., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00166410 · Cited by 806
CFTR Function and Prospects for Therapy
Riordan, J. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142532 · Cited by 610
Physicochemical properties of mucus and their impact on transmucosal drug delivery
Leal, J., Smyth, H. D. C., & Ghosh, D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.018 · Cited by 560
Ratjen, F., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 546
Airway Surface Dehydration in Cystic Fibrosis: Pathogenesis and Therapy
Boucher, R. C. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.071905.105316 · Cited by 512
Self-citationHigh treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Voynow, J. A., & Rubin, B. K. (2009) · Chest · doi:10.1378/chest.08-0412 · Cited by 504
Rowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0703oc · Cited by 492
Self-citationExacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Goss, C. H., & Burns, J. L. (2007) · Thorax · doi:10.1136/thx.2006.060889 · Cited by 445
Innate and Induced Resistance Mechanisms of Bacterial Biofilms
Anderson, G. G., & O'Toole, G. A. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75418-3_5 · Cited by 438
Quittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., & Montgomery, A. B. (2009) · Chest · doi:10.1378/chest.08-1190 · Cited by 400
Muco-Obstructive Lung Diseases
Boucher, R. C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1813799 · Cited by 398
Self-citationCystic fibrosis lung environment and Pseudomonas aeruginosa infection
Bhagirath, A. Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., & Duan, K. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0339-5 · Cited by 378
Physiology and pathophysiology of human airway mucus
Hill, D. B., Button, B., Rubinstein, M., & Boucher, R. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2021 · Cited by 366
Self-citationEvidence for airway surface dehydration as the initiating event in CF airway disease
Boucher, R. C. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01744.x · Cited by 356
Self-citationSuk, J. S., Lai, S. K., Wang, Y.-Y., Ensign, L. M., Zeitlin, P. L., Boyle, M. P., & Hanes, J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.076 · Cited by 352
Effective mucus clearance is essential for respiratory health
Randell, S. H., & Boucher, R. C. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0082sf · Cited by 335
Rheology of Gastric Mucin Exhibits a pH-Dependent Sol−Gel Transition
Celli, J. P., Turner, B. S., Afdhal, N. H., Ewoldt, R. H., McKinley, G. H., Bansil, R., & Erramilli, S. (2007) · Biomacromolecules · doi:10.1021/bm0609691 · Cited by 310
Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
Retsch-Bogart, G. Z., Quittner, A. L., Gibson, R. L., Oermann, C. M., McCoy, K. S., Montgomery, A. B., & Cooper, P. J. (2009) · Chest · doi:10.1378/chest.08-1421 · Cited by 281
Cystic fibrosis: a disease of vulnerability to airway surface dehydration
Boucher, R. C. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.05.001 · Cited by 273
Self-citationHeijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Clunes, L. A., Davies, C. M., Coakley, R. D., Aleksandrov, A. A., Henderson, A. G., Zeman, K. L., Worthington, E. N., Gentzsch, M., Kreda, S. M., Cholon, D., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-192377 · Cited by 261
Self-citationCFTR: cystic fibrosis and beyond
Mall, M. A., & Hartl, D. (2014) · European Respiratory Journal · doi:10.1183/09031936.00228013 · Cited by 259
Acidic pH increases airway surface liquid viscosity in cystic fibrosis
Tang, X. X., Ostedgaard, L. S., Hoegger, M. J., Moninger, T. O., Karp, P. H., McMenimen, J. D., Choudhury, B., Varki, A., Stoltz, D. A., & Welsh, M. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83922 · Cited by 254
Cystic Fibrosis Lung Disease: An Overview
Turcios, N. L. (2020) · Respiratory Care · doi:10.4187/respcare.06697 · Cited by 217
Sawicki, G. S., Rasouliyan, L., McMullen, A. H., Wagener, J. S., McColley, S. A., Pasta, D. J., & Quittner, A. L. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21325 · Cited by 106
Major, T. A., Panmanee, W., Mortensen, J. E., Gray, L. D., Hoglen, N., & Hassett, D. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00379-10 · Cited by 61
Health-related quality of life in cystic fibrosis
Royce, F. H., & Carl, J. C. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834a7829 · Cited by 27
Solé, A., Pérez, I., Vázquez, I., Pastor, A., Escrivá, J., Sales, G., Hervás, D., Glanville, A. R., & Quittner, A. L. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.1233 · Cited by 26
Metadata
- Authors
- Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., & Boucher, R. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-19
- Volume
- 354
- Issue
- 3
- Pages
- 241-250
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108676410
- Cited by
- 694
- References
- 18
- FWCI
- 42.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.